PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

Sharewise Presentation 22/7/24, page-48

  1. 688 Posts.
    lightbulb Created with Sketch. 129
    There is zero evidence of anything much other than that iPPS is superior to current treatments for OA.
    I agree that whilst there is no green light from the FDA, we are not the ones negotiating from a position of strength.
    I also believe that Scott Williams and Matthew Fry, both with big stakes in this venture, are not sitting around waiting to rubber stamp silly ideas.

    I also believe that the FDA, even if we imagine that they are all corrupt and working against us, could not hold back this tide. They would not have given us FT. They would not and could not argue that this drug is not better for pain, function, and wellbeing, than opioids.

    They are doing what Mozz has been doing for many years - poking and prodding it to see what it really is,
    I have lived the same history here that you have, and I am tired and frustrated ......... and the longer this takes, the more it says to me they haven't found anything to warrant concern.

    I just bought more.
    Last edited by Babbanap: 24/07/24
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.